posted by Clare Krusing
on June 20, 2016
Washington, D.C. – America’s Health Insurance Plans (AHIP) President and CEO Marilyn Tavenner and Generic Pharmaceutical Association (GPhA) President and CEO Chip Davis released a joint statement praising today’s decision by the Supreme Court in Cuozzo v. Lee. AHIP and GPhA’s joint amicus brief recognized the inter partes review (IPR) process as a critical consumer protection against abusive patent activity in the prescription drug market.
“Today’s decision from the Supreme Court is a significant win for consumers. By protecting and reaffirming the importance of the inter partes review (IPR), the Court recognizes the vital need for an efficient patent review process — one that promotes a competitive, affordable prescription drug market for consumers.”
AHIP is the national trade association representing the health insurance industry. AHIP’s members provide health insurance benefits and supplemental coverage to nearly 200 million Americans. AHIP advocates for public policies that expand access to affordable health care coverage for all Americans through a competitive marketplace that fosters choice, quality and innovation.
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 88 percent of the prescriptions dispensed in the U.S. but consume just 28 percent of the total drug spending. Additional information is available at gphaonline.org. Follow us on twitter: @gpha.